ReviewTherapeutic advances in chronic disease2017
Steps forward in the treatment of pulmonary arterial hypertension: latest developments and clinical opportunities.
Review in Therapeutic advances in chronic disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Effect of Combination Therapy of Endothelin Receptor Antagonist and Phosphodiesterase-5 Inhibitor on Clinical Outcome and Pulmonary Haemodynamics in Patients with Pulmonary Arterial Hypertension: A Meta-Analysis.Clinical drug investigation · 2019Pooled it
- IMPAHCT: A randomized phase 2b/3 study of inhaled imatinib for pulmonary arterial hypertension.Pulmonary circulation · 2024Article
- Predicting Risk of 1-Year Hospitalization Among Patients with Pulmonary Arterial Hypertension.Advances in therapy · 2023Article
- INSPIRE: Safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH).Pulmonary circulation · 2022Article
- Recent Developments in Nanomaterials-Based Drug Delivery and Upgrading Treatment of Cardiovascular Diseases.International journal of molecular sciences · 2022Review
- A Survey-based Estimate of COVID-19 Incidence and Outcomes among Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension and Impact on the Process of Care.Annals of the American Thoracic Society · 2020Article
- Use of eHealth in the management of pulmonary arterial hypertension: review of the literature.BMJ health & care informatics · 2020Review
- Cost-utility analysis of Macitentan Vs. Bosentan in pulmonary atrial hypertension.Journal of family medicine and primary care · 2020Article
- Low dose 100 cGy irradiation as a potential therapy for pulmonary hypertension.Journal of cellular physiology · 2019Article
- Exosomes in Systemic Sclerosis: Messengers Between Immune, Vascular and Fibrotic Components?International journal of molecular sciences · 2019Review
- Elucidation of Vasodilation Response and Structure Activity Relationships ofMolecules (Basel, Switzerland) · 2019Article
- Emerging therapeutics in pulmonary hypertension.American journal of physiology. Lung cellular and molecular physiology · 2018Review
- Pharmacokinetics and tolerability of LIQ861, a novel dry-powder formulation of treprostinil.Pulmonary circulationArticle
- Apoptosis signal-regulating kinase 1 inhibition inPulmonary circulationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary arterial hypertension (PAH) is a chronic disease that results in narrowing of the small pre-capillary pulmonary arteries leading to elevation of pulmonary artery pressure and pulmonary vascular resistance, subsequent right ventricular failure, and if unchecked, death. Advances in the treatment of PAH over the last two decades have markedly improved survival. These improvements reflect a combination of changes in treatments, improved patient care strategies, and varying disease phenotypes in the PAH population. Currently approved therapies for PAH are directed at the recognized abnormalities within the pulmonary vasculature and include endothelin receptor antagonists, phosphodiesterase-5 inhibitors, soluble guanylate cyclase stimulators, and prostacyclin pathway agents. Most of these drugs have been approved on the basis of short-term trials that mainly demonstrated improvements in exercise capacity. More recently, long-term, event-driven trials of novel drugs have been performed, demonstrating new efficacy parameters. There have also been exciting advances in the understanding of right heart failure pathophysiology in PAH that have the potential to inspire the development of right ventricular targeted therapy and continued discoveries in the heterogeneity of disease and response to treatment has great potential for developing more 'personalized' therapeutic options. In this article, we review the current available data regarding the management of PAH, with an emphasis on the pharmacologic therapies and discussion of novel therapeutic directions for the treatment of this fatal disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.